- Home
- SPFI vs JANX Comparison
SPFI vs JANX Comparison
Compare SPFI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | JANX |
|---|---|---|
| Founded | 1941 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 725.9M | 847.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | JANX |
|---|---|---|
| Price | $40.49 | $13.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $46.00 | ★ $47.00 |
| AVG Volume (30 Days) | 72.7K | ★ 889.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $47.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.66 | $12.12 |
| 52 Week High | $45.09 | $35.34 |
Technical Indicators
Market Signals| Indicator | SPFI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 41.85 |
| Support Level | $38.19 | $13.88 |
| Resistance Level | $41.87 | $14.64 |
| Average True Range (ATR) | 0.87 | 0.51 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 61.32 | 34.59 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.